Astragaloside ICAS# 84680-75-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 84680-75-1 | SDF | Download SDF |
| PubChem ID | 13996685 | Appearance | White-beige powder |
| Formula | C45H72O16 | M.Wt | 869.1 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Astrasieversianin IV; Cyclosieversioside B;91739-00-3 | ||
| Solubility | DMSO : 50 mg/mL (57.53 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | [(2S,3R,4S,5R)-3-acetyloxy-5-hydroxy-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-9-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]oxan-4-yl] acetate | ||
| SMILES | CC(=O)OC1C(COC(C1OC(=O)C)OC2CCC34CC35CCC6(C(C(CC6(C5CC(C4C2(C)C)OC7C(C(C(C(O7)CO)O)O)O)C)O)C8(CCC(O8)C(C)(C)O)C)C)O | ||
| Standard InChIKey | KXHCYYSIAXMSPA-OOCCOBHWSA-N | ||
| Standard InChI | InChI=1S/C45H72O16/c1-21(47)56-33-24(50)19-55-38(34(33)57-22(2)48)60-28-11-13-45-20-44(45)15-14-41(7)35(43(9)12-10-29(61-43)40(5,6)54)23(49)17-42(41,8)27(44)16-25(36(45)39(28,3)4)58-37-32(53)31(52)30(51)26(18-46)59-37/h23-38,46,49-54H,10-20H2,1-9H3/t23-,24+,25-,26+,27-,28-,29-,30+,31-,32+,33-,34+,35-,36-,37+,38-,41+,42-,43+,44-,45+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Astragaloside Ι may protect the cerebral tissue against the free radical damage in ischemia and inhibit the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway. It stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway. |
| Targets | Wnt/β-catenin | HIF | TNF-α | NO | NOS | COX | NF-kB | PI3K | Akt | NF-kB | IkB | IL Receptor | IKK |
| In vitro | Astragaloside I Stimulates Osteoblast Differentiation Through the Wnt/β-catenin Signaling Pathway.[Pubmed: 27397144 ]Phytother Res. 2016 Oct;30(10):1680-8.Astragaloside I (As-I), one of the main active ingredients in Astragalus membranaceus, is believed to have osteogenic properties, but this hypothesis has not been investigated in detail.
|
| In vivo | Protective effects of astragalus extract against intermittent hypoxia-induced hippocampal neurons impairment in rats.[Pubmed: 23595393]Chin Med J (Engl). 2013;126(8):1551-4.Intermittent hypoxia is the main pathophysiological cause of the obstructive sleep apnea syndrome. Astragalus shows improvement of spatial learning and memory abilities under intermittent hypoxia. Our study aimed to investigate the protective effect of astragalus against intermittent hypoxia induced-hippocampal neurons impairment in rats and lay the theoretical foundation for the sleep apnea improvement in cognitive function by astragalus.
|
| Cell Research | Astragaloside I inhibited the activation of BV-2 cell induced by LPS through modulation of PI3K/Akt/NF-κB pathway[Reference: WebLink]China Journal of Traditional Chinese Medicine & Pharmacy, 2016(05).To investigate the effect and mechanism of Astragaloside I(AST I) on the activation of microglial cell line BV-2 induced by LPS.
|
| Animal Research | Effects of Astragaloside I on Cerebral GSH-px and MDA Contents Following Middle Cerebral Artery Occlusion in Mice[Reference: WebLink]Chinese Journal of Clinical Neurosciences, 1998(03):146-8.Free radicals formation and lipid peroxidation were thought to potentiate ischemic brain cell injury.
|
Astragaloside I Dilution Calculator
Astragaloside I Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1506 mL | 5.7531 mL | 11.5062 mL | 23.0123 mL | 28.7654 mL |
| 5 mM | 0.2301 mL | 1.1506 mL | 2.3012 mL | 4.6025 mL | 5.7531 mL |
| 10 mM | 0.1151 mL | 0.5753 mL | 1.1506 mL | 2.3012 mL | 2.8765 mL |
| 50 mM | 0.023 mL | 0.1151 mL | 0.2301 mL | 0.4602 mL | 0.5753 mL |
| 100 mM | 0.0115 mL | 0.0575 mL | 0.1151 mL | 0.2301 mL | 0.2877 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Astragaloside I is a natural product isolated from Astragalus.
References:
[1]. JIN Yi-qun, et al. Determination of astragaloside-I content in Qidan Jiannao Granules with HPLC-ELSD. Acta Chinese Medicine and Pharmacology, 2006-02
[2]. Wang chunhong, et al. Determination the Content of Astragaloside I in Shuxing Oral by Dual Wavelength TLC-Scanning. China Pharmacist, 2005-05
- 3-O-(2'E,4'Z-Decadienoyl)ingenol
Catalog No.:BCN3767
CAS No.:84680-59-1
- Enalaprilat Dihydrate
Catalog No.:BCC5009
CAS No.:84680-54-6
- Astragaloside II
Catalog No.:BCN5962
CAS No.:84676-89-1
- Isoastragaloside I
Catalog No.:BCN2979
CAS No.:84676-88-0
- Lorcaserin HCl
Catalog No.:BCC5041
CAS No.:846589-98-8
- Decinnamoyltaxinine J
Catalog No.:BCN7210
CAS No.:84652-33-5
- Tea polyphenol
Catalog No.:BCN8518
CAS No.:84650-60-2
- 4-Nitrobenzyl dimethylcarbamate
Catalog No.:BCN3284
CAS No.:84640-31-3
- Eurycomanone
Catalog No.:BCN2990
CAS No.:84633-29-4
- Itraconazole
Catalog No.:BCC4914
CAS No.:84625-61-6
- H-Lys(Fmoc)-OH
Catalog No.:BCC2984
CAS No.:84624-28-2
- Boc-Lys(Fmoc)-OH
Catalog No.:BCC3417
CAS No.:84624-27-1
- Astragaloside III
Catalog No.:BCN5963
CAS No.:84687-42-3
- Astragaloside IV
Catalog No.:BCN5960
CAS No.:84687-43-4
- Arglabin
Catalog No.:BCC5299
CAS No.:84692-91-1
- UVI 3003
Catalog No.:BCC7638
CAS No.:847239-17-2
- Calceolarioside A
Catalog No.:BCN5347
CAS No.:84744-28-5
- Qingyangshengenin
Catalog No.:BCN4389
CAS No.:84745-94-8
- Eriocalyxin B
Catalog No.:BCN4390
CAS No.:84745-95-9
- CEP-18770
Catalog No.:BCC2093
CAS No.:847499-27-8
- SHA 68
Catalog No.:BCC6210
CAS No.:847553-89-3
- NVP-BEP800
Catalog No.:BCC2129
CAS No.:847559-80-2
- ICG 001
Catalog No.:BCC3632
CAS No.:847591-62-2
- Tasumatrol L
Catalog No.:BCN6955
CAS No.:847835-17-0
Protective effects of astragalus extract against intermittent hypoxia-induced hippocampal neurons impairment in rats.[Pubmed:23595393]
Chin Med J (Engl). 2013;126(8):1551-4.
BACKGROUND: Intermittent hypoxia is the main pathophysiological cause of the obstructive sleep apnea syndrome. Astragalus shows improvement of spatial learning and memory abilities under intermittent hypoxia. Our study aimed to investigate the protective effect of astragalus against intermittent hypoxia induced-hippocampal neurons impairment in rats and lay the theoretical foundation for the sleep apnea improvement in cognitive function by astragalus. METHODS: Male Wistar rats were divided into 4 groups: blank control group, normoxia group, intermittent hypoxia group and astragalus treated intermittent hypoxia group. After 6-week treatment, apoptosis of neurons was evaluated by terminal deoxynucleotidyl-transferase-mediated dUTP nick end-labeling (TUNEL) assay. Furthermore, the expression of HIF-1a was detected by real-time reverse transcription polymerase chain reaction (RT-PCR) at the mRNA level as well as by immunohistochemistry (IHC) and Western blotting at the protein level. RESULTS: HPLC analysis indicated that Astragaloside IV, Astragaloside II and Astragaloside I were the main compounds in astragals extract. Astragalus extract reduced the apoptosis of hippocampal neurons (P < 0.05) and decreased the expression of HIF-1a at both the mRNA and protein levels in hippocampus compared with non-treated groups (P < 0.05). CONCLUSION: Astragalus protects against intermittent hypoxia-induced hippocampal neurons impairment in rats.
Astragaloside I Stimulates Osteoblast Differentiation Through the Wnt/beta-catenin Signaling Pathway.[Pubmed:27397144]
Phytother Res. 2016 Oct;30(10):1680-1688.
Astragaloside I (As-I), one of the main active ingredients in Astragalus membranaceus, is believed to have osteogenic properties, but this hypothesis has not been investigated in detail. In the present work, the As-I-induced osteogenic effects and its underlying mechanism were studied in MC3T3-E1 cells. The results indicated that the cellular levels of ALP and extracellular matrix calcium increased in a dose-dependent manner by As-I. To clarify the mechanisms involved in this process, the effect of As-I on the key osteogenic-related genes was investigated. We found that As-I stimulated the expression of beta-catenin and Runx2 in MC3T3-E1 cells, which play central roles in the Wnt/beta-catenin signaling pathway, suggesting that As-I could promote osteoblastic differentiation by regulating the Wnt/beta-catenin signaling pathway. Moreover, the osteogenic effect of As-I could be inhibited by DKK-1, which is the classical inhibitor of Wnt/beta-catenin-signaling pathway. Furthermore, As-I also increased BMP-2, BGP and OPG/RANKL expression, which are also activated by Wnt/beta-catenin signaling pathway. Taken together, our findings show that As-I stimulates osteoblast differentiation through the Wnt/beta-catenin signaling pathway, which also activates the BMP pathway and RANK pathway, thus highlighting the As-I for pharmaceutical and medicinal applications such as treating bone disease. Copyright (c) 2016 John Wiley & Sons, Ltd.
